Tiziana Life Sciences to Host Virtual Key Opinion Leader Event to Discuss Intranasal Administration of Foralumab in Multiple SclerosisMonday, March 14 at 11:00 am ET, registration details below

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies through novel drug delivery routes, announced today that will host a Key Opinion Leader (KOL) virtual webinar event titled “Foralumab Clinical Update in Multiple Sclerosis: A Landmark Study with Intranasal Immunotherapy” on Monday, March 14, 2022 at 11:00 a.m. Eastern Time.

This webinar includes presentations to discuss clinical data and the importance of intranasal foralumab immunotherapy in neurodegenerative diseases. Prof. Howard Weiner, MD, of Harvard Medical School, Prof. Tanuja Chitnis, MD, of Massachusetts General Hospital, Prof. Tarun Singhal, MD, of Brigham and Women’s Hospital, and Prof. Lawrence Steinman, MD, of Stanford Medicine this is discussed by the current treatment landscape in inflammatory neurodegenerative diseases and the potential of new, locally acting immunotherapies capable of crossing the blood-brain barrier, presenting a unique challenge for drug delivery to the central nervous system. As part of the discussion, the KOLs will discuss clinical data related to intranasal foralumab in multiple sclerosis reported by Tiziana on March 10, 2022.

Tiziana is currently evaluating an innovative and proprietary formulation of foralumab, a fully human anti-CD3 monoclonal antibody for intranasal administration for the treatment of Secondary Progressive Multiple Sclerosis (SPMS), and recently announced positive clinical data from SPMS patients followed for six months treated with intranasally administered foralumab.

A live question and answer session will follow. To register for the event and pre-submit questions for management or KOLs, please clickHere.

About the KOLs

Howard L. Weiner, MD, is the Robert L. Kroc Professor of Neurology at Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center, and Co-Director of the Center for Neurological Disorders at Brigham & Women’s Hospital. dr In 2000, Weiner founded the Partners Multiple Sclerosis Center at Brigham & Women’s Hospital, which combines clinical evaluation, MRI imaging and immune monitoring and is the first integrated MS center to bring these disciplines into the individual care of MS patients. dr Weiner pioneered the use of immunotherapy and the drug cyclophosphamide to treat multiple sclerosis and studied immune abnormalities in the disease, including the role of the innate immune system and regulatory T cells. He also pioneered the use of the mucosal immune system to treat autoimmune and other diseases, including ALS, Huntington’s disease and stroke. Based on his work, vaccines are being tested for multiple sclerosis, diabetes and, more recently, Alzheimer’s disease. He is also developing new therapeutic options for neuromyelitis optica (NMO).

dr Weiner is the author of Curing MS: How Science is Solving the Mystery of Multiple Sclerosis, which chronicles the history of MS, his more than 30 years of research and clinical management of MS, and his “21 Point Hypothesis” in Detail describes etiology and treatment of multiple sclerosis. In 2004, Harvard Medical School honored Dr. Weiner with the establishment of the Howard L. Weiner Professor of Neurology Endowed Chair.

Tanuja Chitnis, MD, is director of the Mass General Brigham Pediatric MS Center at the Mass General Hospital for Children. She also sees adult patients with MS at Brigham and Women’s Hospital. She completed her medical training at the University of Toronto Medical School, her residency in neurology in Philadelphia, and a fellowship in multiple sclerosis and neuroimmunology at Brigham and Women’s Hospital, Harvard Medical School. dr Chitnis has long had an interest in pediatric MS. She is chair of the International Pediatric MS Workgroup and has authored many publications and reviews on multiple sclerosis. She is actively involved in several research projects aimed at improving the understanding and management of MS in children.

Tarun Singhal, MD is Director of the PET Neurological Disease Imaging Program at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital and is an Assistant Professor of Neurology at Harvard Medical School and in Boston, MA. dr Singhal received his medical degree from All India Institute of Medical Sciences and completed his residency in Nuclear Medicine in India before coming to the United States in 2006. He completed postdoctoral fellowships at the Yale PET Center and the Kettering PET Center, followed by neurology and nuclear medicine residencies and fellowships at Harvard. He is a board-certified neurologist and nuclear medicine physician and has been a Harvard faculty member since 2014. dr Singhal has led several molecular imaging projects in the field of neuroscience, including work on [C-11]methionine PET in brain tumors, norepinephrine transporter imaging of the central nervous system, and more recently, neuroinflammation PET imaging in multiple sclerosis and related diseases. dr Singhal maintains an active clinical practice examining MS patients in addition to directing the PET neurological disease imaging program at Brigham and Women’s Hospital.

Lawrence Steinman, MD is Professor of Neurology and Neurological Sciences, Pediatrics and Genetics. From 2003 to 2011, he also served as the chair of Stanford University’s Interdepartmental Program in Immunology.

dr Steinman’s research focuses on what causes flare-ups and remissions in multiple sclerosis (MS), the type of molecules that act as a brake on brain inflammation, and finding a tolerancing vaccine for autoimmune diseases like type 1 diabetes and neuromyelitis optica. He has developed two antigen-specific therapies for MS and type 1 diabetes using DNA vaccines. He was senior author of the landmark 1992 Nature paper that reported the key role of a particular integrin in encephalitis. This research led to the development of the drug Tysabri, which is used to treat patients with MS and Crohn’s disease.

About Tiziana Life Sciences, Ltd.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformative drug delivery technologies to enable alternative avenues of immunotherapy. Tiziana’s innovative nasal, oral and inhaled approaches under development have the potential to offer improvements in efficacy, safety and tolerability compared to intravenous (IV) administration. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have demonstrated favorable safety profiles and clinical responses in patients in previous studies. Tiziana’s technology for alternative routes of immunotherapy has been patented, with multiple applications pending, and is expected to enable a broad application pipeline.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on the Company’s current expectations, estimates and projections about its industry; his beliefs; and assumptions. Words such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “seek”, “estimate” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company’s control, are difficult to predict and could cause actual results to differ materially from those stated or projected in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the Company’s views only as of the date of this announcement. The forward-looking statements made in this release speak only to events as of the date the statements are made. The Company undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement, except as required by law or any applicable regulatory authority.

Irina Kofler
LifeSci Advisor
Tel: (646) 970-4681
[email protected]

Tiziana Life Sciences Ltd
Hana Malik, Business Development and Investor Relations Manager
+44 (0) 207 495 2379
[email protected]

Primary logo

Comments are closed.